Zubsolv 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0023 
A.5.a - Administrative change - Change in the name 
05/10/2023 
and/or address of a manufacturer/importer 
responsible for batch release 
amended 
on 
Annex II and 
PL 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/09/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0022 
A.4 - Administrative change - Change in the name 
27/06/2023 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IA/0020 
B.II.b.2.a - Change to importer, batch release 
24/04/2023 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
R/0019 
Renewal of the marketing authorisation. 
19/05/2022 
27/07/2022 
SmPC, Annex 
II, Labelling 
and PL 
IB/0018/G 
This was an application for a group of variations. 
28/01/2022 
n/a 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
IAIN/0017/G 
This was an application for a group of variations. 
18/01/2022 
n/a 
B.II.b.2.c.1 - Change to importer, batch release 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
II/0015 
B.II.d.1.f - Change in the specification parameters 
02/09/2021 
n/a 
and/or limits of the finished product - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the finished product 
IAIN/0016 
To update section 4.4 of the SmPC and section 2 of 
07/06/2021 
27/07/2022 
SmPC and PL 
the PL to include sleep-related breathing disorders. 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
T/0014 
Transfer of Marketing Authorisation 
04/03/2021 
22/03/2021 
SmPC, 
Labelling and 
PL 
IB/0013 
B.II.c.1.z - Change in the specification parameters 
22/12/2020 
n/a 
and/or limits of an excipient - Other variation 
IB/0012 
B.I.b.1.z - Change in the specification parameters 
22/12/2020 
n/a 
and/or limits of an AS, starting 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Other variation 
IB/0011 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
22/12/2020 
22/03/2021 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0010/G 
This was an application for a group of variations. 
04/12/2020 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IAIN/0009 
C.I.z - Changes (Safety/Efficacy) of Human and 
17/09/2020 
22/03/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
PSUSA/2113/
Periodic Safety Update EU Single assessment - 
14/05/2020 
n/a 
PRAC Recommendation - maintenance 
201909 
buprenorphine / naloxone 
IB/0007 
C.I.11.z - Introduction of, or change(s) to, the 
19/02/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0006 
B.II.b.1.b - Replacement or addition of a 
25/07/2019 
n/a 
manufacturing site for the FP - Primary packaging 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
site 
IAIN/0005/G 
This was an application for a group of variations. 
31/05/2019 
n/a 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.c.1.c - Change in the specification parameters 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
T/0004 
Transfer of Marketing Authorisation 
15/03/2019 
17/04/2019 
SmPC, 
Labelling and 
PL 
T/0003 
Transfer of Marketing Authorisation 
12/11/2018 
17/12/2018 
SmPC, 
Labelling and 
PL 
IB/0002/G 
This was an application for a group of variations. 
02/05/2018 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
IB/0001/G 
This was an application for a group of variations. 
02/02/2018 
17/12/2018 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Page 6/8 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
Page 7/8 
 
 
 
 
 
the range of the currently approved pack sizes 
Page 8/8 
 
 
 
 
 
 
 
